NEW YORK, June 2 - Devgen has completed a research collaboration with Genentech using RNAi in C. elegans to elucidate the role of genes in cellular pathways related to cancer, the company said today.
Devgen, of Ghent, Belgium, has created a genome-wide library of RNA interference sequence to suppress the activity of of the 19,000 C. elegans genes. Devgen plans to use the library in drug-target identification and functional validation. It uses the RNAi along with its Function Factory, a database that includes the phenotypic profiles of C. elegans mutants as well as the effect of gene knockdowns, drugs, and other compounds on the mutants.
The parties did not disclose the financial terms of the agreement.